Paceline Bio
New accelerator entry · 2025-10-14 · the record
Paceline Bio runs the research and clinical ops layer behind biotech and pharma company who want to move fast, starting with biospecimen collection, logistics, and storage. We're built to get you from scope to signature in just one session so you can accelerate your programs today.
Paceline Bio is a Y Combinator company in the Fall 2025 batch. Its directory entry describes it as: Accelerating clinical ops for biotech & pharma (Y Combinator directory entry, October 14, 2025).
Sell to companies like Paceline Bio? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2025-10-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Paceline Bio.
Free to see. No signup.
More on Paceline Bio and the records around it.
Same batch, Healthcare first.
Get an email when Paceline Bio changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Paceline Bio raises, hires or launches. No email unless you switch it on.
Watch Paceline Bio →Get the full cited report on Paceline Bio
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Paceline Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Paceline Bio runs the research and clinical ops layer behind biotech and pharma company who want to move fast, starting with biospecimen collection, logistics, and storage. We're built to get you from scope to signature in just one session so you can accelerate your programs today.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Paceline Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Paceline Bio covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Paceline BioYou get an alert in MentionFox the next time this company shows up.
If you're behind Paceline Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Paceline Bio. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.

https://mentionfox.com/funding/yc-paceline-bio